MarketFriction

Parmax Pharma Ltd

BSE 540359 · Pharmaceuticals
₹137.75 +0.99%
BSE close2026-09-28
Market cap₹94.8 Cr.

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Standalone, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales4.071.334.267.829.286.284.831.942.534.333.318.22
Expenses4.842.485.067.319.086.175.392.194.124.534.867.39
Operating Profit-0.77-1.15-0.800.510.200.11-0.56-0.25-1.59-0.20-1.550.83
OPM %-18.92%-86.47%-18.78%6.52%2.16%1.75%-11.59%-12.89%-62.85%-4.62%-46.83%10.10%
Other Income0.010.010.010.010.120.01-1.170.010.010.010.032.08
Interest0.180.160.160.110.130.110.240.280.240.280.500.23
Depreciation0.430.450.410.400.400.41-0.180.240.260.270.250.48
Profit before tax-1.37-1.75-1.360.01-0.21-0.40-1.79-0.76-2.08-0.74-2.272.20
Tax %0.00%0.00%6.62%0.00%0.00%0.00%-16.76%0.00%0.00%0.00%-74.45%0.00%
Net Profit-1.37-1.75-1.450.01-0.22-0.39-1.49-0.76-2.08-0.73-0.582.20
EPS in Rs-3.66-4.68-3.880.03-0.59-1.04-3.98-2.03-5.56-1.95-1.555.88
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales0.000.0011.8911.9920.9226.1718.2415.3911.0228.2012.1118.39
Expenses0.050.0510.8110.8819.1522.7415.6713.1414.3927.9415.7520.90
Operating Profit-0.05-0.051.081.111.773.432.572.25-3.370.26-3.64-2.51
OPM %9.08%9.26%8.46%13.11%14.09%14.62%-30.58%0.92%-30.06%-13.65%
Other Income0.060.060.050.050.100.090.060.040.05-1.030.052.13
Interest0.000.000.040.030.130.370.390.370.620.591.241.25
Depreciation0.000.001.091.031.011.941.931.881.711.031.011.26
Profit before tax0.010.010.000.100.731.210.310.04-5.65-2.39-5.84-2.89
Tax %200.00%100.00%20.00%41.10%38.02%54.84%375.00%1.77%-12.55%-28.94%
Net Profit0.00-0.010.000.080.430.750.14-0.10-5.75-2.09-4.16-1.19
EPS in Rs0.00-0.030.000.211.152.000.37-0.27-15.37-5.59-11.12-3.18
Dividend Payout %0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth%-14%-8%-18%
Compounded Profit Growth%%%34%
Stock Price CAGR%29%64%330%
Return on Equity%%%%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital4.034.454.454.454.454.454.454.454.454.454.454.45
Reserves0.120.110.100.110.180.611.371.511.40-4.35-6.44-10.60
Borrowings0.790.461.021.965.525.265.895.185.375.918.0912.06
Other Liabilities0.040.062.1410.119.5610.7511.016.836.399.3212.6522.14
Total Liabilities4.985.087.7116.6319.7121.0722.7217.9717.6115.3318.7528.05
Fixed Assets2.532.532.725.864.929.6410.8410.449.509.277.977.86
CWIP0.000.000.000.003.330.000.000.000.000.100.000.00
Investments0.000.000.000.000.200.200.200.000.000.000.400.40
Other Assets2.452.554.9910.7711.2611.2311.687.538.115.9610.3819.79
Total Assets4.985.087.7116.6319.7121.0722.7217.9717.6115.3318.7528.05
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity-0.060.00-0.503.880.922.823.530.750.33-0.20-0.66-2.36
Cash from Investing Activity0.000.00-0.19-4.23-3.41-2.40-3.15-1.53-0.94-1.59-0.70-0.90
Cash from Financing Activity0.000.100.561.143.10-0.230.40-0.91-0.041.431.403.81
Net Cash Flow-0.060.09-0.140.790.610.200.78-1.69-0.65-0.360.040.56
Free Cash Flow-0.060.00-0.69-0.35-2.490.420.38-0.78-0.61-1.79-1.36-3.26
CFO/OP300%0%1,000%359%83%159%103%29%15%6%-254%65%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days60.4835.0157.5823.0113.6114.7060.2816.5795.24
Inventory Days203.34278.6688.17107.27154.80286.55123.7456.09290.01
Days Payable609.39645.07311.84269.40299.82309.82382.60173.18529.77
Cash Conversion Cycle-345.57-331.40-166.09-139.12-131.41-8.57-198.58-100.52-144.52
Working Capital Days-59.86-71.84-56.18-48.26-36.02-0.47-115.59-54.23-200.43
ROCE %0.81%0.20%0.19%0.66%1.56%8.40%14.34%6.13%3.67%-58.39%-12.06%-76.60%
Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters30.80%30.83%30.80%30.80%30.80%30.80%30.80%30.80%30.80%30.80%30.80%64.66%
Public69.19%69.16%69.19%69.20%69.20%69.20%69.21%69.21%69.20%69.21%69.20%35.33%
No. of Shareholders2,0022,0992,1852,2462,3342,3562,3772,3992,3932,3882,2732,151

Fundamentals

Market Cap₹ 94.8 Cr.
Current Price₹ 138
Book Value₹ -16.4
ROCE-76.6 %
ROE%
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)-18%
Compounded Profit Growth (TTM)34%
Standalone figures.
Valuation
Market capRs 95 Cr
Enterprise valueRs 106 Cr
Price to book-15.41x
Price to sales5.15x
EV / sales5.77x
Earnings yield-1.26%
P/B, 3-year average45.25x
P/E, 5-year average188.50x
P/B, 5-year average28.71x
Profitability
Operating margin (excl. other income)-30.06%
Operating margin (incl. other income)-29.64%
EBITDA margin-2.07%
Pre-tax margin-15.72%
Net profit margin-6.47%
Net margin, latest quarter26.76%
ROE102.21%
ROCE-76.60%
ROA-17.78%
ROE, 3-year average43.37%
ROCE, 3-year average-54.91%
ROA, 3-year average-21.65%
ROE, 5-year average26.16%
ROCE, 5-year average-30.98%
ROA, 5-year average-12.97%
ROIC (approx.)-22.16%
Tax rate28.94%
Other income / net worth-0.81%
Growth
Sales growth (latest year)-57.06%
Sales CAGR, 3 years-7.68%
Sales CAGR, 5 years-14.28%
Sales growth QoQ148.34%
Sales growth YoY (latest quarter)323.71%
Per share
EPS (TTM)Rs -1.73
EPS (latest year)Rs -2.23
EPS (latest quarter)Rs 3.20
EPS, 3-year averageRs -4.08
EPS, 5-year averageRs -2.44
Book value per shareRs -8.94
Sales per shareRs 26.73
Cash flow per shareRs -3.43
Free cash flow per shareRs -4.74
Efficiency
Asset turnover0.43x
Fixed asset turnover1.54x
Inventory turnover1.54x
Inventory days237 days
Debtor days95 days
Debtors turnover3.83x
Creditor days530 days
Cash conversion cycle-145 days
Working capital days-200 days
Leverage
Total debtRs 12 Cr
Cash and bankRs 1 Cr
Net debtRs 11 Cr
Debt to equity-1.96x
Interest coverage-1.31x
Owners' fund to total sources-21.93%
Debt to assets42.99%
Cash flow
Cash from Operating Activity (latest year)Rs -2 Cr
Cash from Investing Activity (latest year)Rs -1 Cr
Cash from Financing Activity (latest year)Rs 4 Cr
Net Cash Flow (latest year)Rs 1 Cr
Free cash flow (latest year)Rs -3 Cr
FCFE (approx.: FCF + change in debt)Rs 1 Cr
Statement figures
Net sales (TTM)Rs 18 Cr
Net sales (latest year)Rs 12 Cr
Sales (latest quarter)Rs 8 Cr
Operating profit excl. other income (latest year)Rs -4 Cr
Operating profit (latest quarter)Rs 1 Cr
Other income (TTM)Rs 2 Cr
EBITDA (TTM)Rs -0 Cr
PBDT (TTM)Rs -2 Cr
Profit before tax (TTM)Rs -3 Cr
Tax (latest year)Rs -2 Cr
Net profit (TTM)Rs -1 Cr
Net profit (latest year)Rs -4 Cr
Net profit (latest quarter)Rs 2 Cr
Depreciation (TTM)Rs 1 Cr
Depreciation (latest quarter)Rs 0 Cr
Interest (TTM)Rs 1 Cr
Cost of goods sold (latest year)Rs 12 Cr
Total expenditure (latest year)Rs 16 Cr
Total income (latest year)Rs 12 Cr
Share capitalRs 4 Cr
ReservesRs -11 Cr
Shareholders' fundsRs -6 Cr
Total assetsRs 28 Cr
Net blockRs 8 Cr
InvestmentsRs 0 Cr
ReceivablesRs 3 Cr
InventoryRs 8 Cr
Other liabilitiesRs 22 Cr
Shares outstanding (crore)0.69
Ownership
Promoter holding64.66% (+33.86 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
Period540359Nifty 50Difference
1 week+6.0%-2.8% +8.8 pts
1 month+28.8%-6.8% +35.6 pts
3 months+253.2%-7.6% +260.8 pts
3 years+343.5%+14.2% +329.3 pts
5 years+262.0%+27.9% +234.1 pts

Red flags

F-score 3 of 8
seriousNegative equity Shareholders' equity is negative
explainReceivables outrunning sales Receivables grew 147% vs sales -57% in 2026
explainDebt up, profit down Borrowings up 49% while net profit fell in 2026
lookInventory outrunning sales Inventory grew 137% vs sales -57% in 2026
lookRepeated losses Net loss in each of the last two years
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹8 Cr +323.7% vs Jun 2025. Net profit ₹2 Cr +389.5%.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.

Quick answers

What is the market cap of Parmax Pharma Ltd?

Parmax Pharma Ltd (540359) has a market capitalisation of Rs 94.8 Cr. at the 2026-09-28 close.

What were Parmax Pharma Ltd's latest quarterly results?

In the Jun 2026 quarter, Parmax Pharma Ltd sales was Rs 8 Cr (+323.7% vs Jun 2025) and net profit was Rs 2 Cr.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03